IMA

Insider Trades

Name	Value	Action	Price	Current Price
Bonita David PDirector $385384.7k shares BuyApr 14, 2026 $0.001 --
Bonita David PDirector $337336.6k shares BuyApr 14, 2026 $0.001 --
Orbimed Advisors LLCDirector $385384.7k shares BuyApr 14, 2026 $0.001 --
Orbimed Advisors LLCDirector $337336.6k shares BuyApr 14, 2026 $0.001 --
Slattery Joseph PDirector $96k16k shares BuyDec 24, 2025 $5.99 --
Bonita David PDirector $2.5M83.6k shares BuyJul 25, 2025 $29.90 --

News

globenewswire.comImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New Yorkglobenewswire.comMay 27

globenewswire.comImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Updateglobenewswire.comMay 7

benzinga.comImageneBio $30 Million Private Placement Ignites Stockbenzinga.comApr 13

globenewswire.comImageneBio Announces $30 Million Private Placementglobenewswire.comApr 13

Trade IMA

About ImageneBio Inc

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

CEO: Kristin Yarema
IPO Date: Feb 27, 1998

Market Data

Open: $5.76
High: $5.76
Low: $5.52
Volume: 48
52W High: $18.00
52W Low: $3.94

Valuation

Market Cap: $63M
Enterprise Value: $-4.7M

Financials

Free Cash Flow: $-48M
Revenue: $800k
Net Income: $-45M
Cash: $35M
Debt: $10.0M

Events

EarningsJul 23

EPS est. -0.97667